Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.

Curr Cardiol Rev · 2014 · PMC4101192 · PMID 24821657

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significancep=0.13not close (p > 0.1)

All-cause mortality was lower with dabigatran (4.13%/year for warfarin, 3.75%/year for dabigatran, 110 mg bid, 3.64%/year for dabigatran, 150 mg bid), but did not reach statistical significance (p=0.13 and p=0.051 for the 110 mg and 150 mg bid doses, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.